EGFR and non-small cell lung carcinoma: In a recent study conducted by Aredo et al., they reported that stage III EGFR-mutated NSCLC patients did not benefit from post-CCRT consolidation durvalumab therapy and experienced a high frequency of immune-related adverse events (irAEs) [30].